BSE Live
Apr 20, 16:01Prev. Close
258.50
Open Price
259.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 20, 15:56Prev. Close
258.22
Open Price
259.98
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
268.30 (114)
| Profit & Loss account of Medicamen Biotech (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 149.24 | 170.96 | 137.43 | 108.29 | 108.15 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 149.24 | 170.96 | 137.43 | 108.29 | 108.15 | |
| Total Operating Revenues | 151.46 | 172.39 | 137.88 | 115.45 | 110.15 | |
| Other Income | 6.23 | 2.30 | 2.46 | 1.72 | 0.75 | |
| Total Revenue | 157.69 | 174.69 | 140.35 | 117.17 | 110.90 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 88.83 | 104.70 | 81.80 | 55.69 | 65.84 | |
| Purchase Of Stock-In Trade | 5.60 | 3.58 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 13.88 | 13.20 | 9.74 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -11.68 | -16.89 | -10.30 | -3.34 | 1.04 | |
| Employee Benefit Expenses | 21.57 | 22.12 | 18.57 | 14.50 | 8.79 | |
| Finance Costs | 3.05 | 4.38 | 2.92 | 1.40 | 1.06 | |
| Depreciation And Amortisation Expenses | 6.96 | 7.01 | 6.35 | 5.77 | 2.52 | |
| Other Expenses | 30.58 | 32.92 | 9.79 | 11.83 | 5.16 | |
| Total Expenses | 144.91 | 157.80 | 123.01 | 99.06 | 94.15 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 12.77 | 16.89 | 17.33 | 18.10 | 16.75 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 12.77 | 16.89 | 17.33 | 18.10 | 16.75 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 3.64 | 4.22 | 3.70 | 3.98 | 4.15 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -0.31 | -0.63 | -1.37 | -0.78 | 0.12 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 3.33 | 3.59 | 2.33 | 3.20 | 4.26 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 9.45 | 13.30 | 15.00 | 14.91 | 12.49 | |
| Profit/Loss From Continuing Operations | 9.45 | 13.30 | 15.00 | 14.91 | 12.49 | |
| Profit/Loss For The Period | 9.45 | 13.30 | 15.00 | 14.91 | 12.49 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 7.43 | 10.50 | 12.04 | 12.20 | 10.22 | |
| Diluted EPS (Rs.) | 7.43 | 10.50 | 12.04 | 12.20 | 10.22 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 1.27 | 1.27 | 1.22 | 0.61 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
26.11.2025
Medicamen Bio Consolidated September 2025 Net Sales at Rs 47.17 crore, up 5.42% Y-o-Y
24.11.2025
Medicamen Bio Standalone September 2025 Net Sales at Rs 42.23 crore, down 1.44% Y-o-Y
09.09.2025
Medicamen Bio Standalone June 2025 Net Sales at Rs 38.45 crore, down 7.31% Y-o-Y
11.06.2025
Medicamen Bio Standalone March 2025 Net Sales at Rs 26.00 crore, down 42.24% Y-o-Y
26.11.2025
Medicamen Bio Consolidated September 2025 Net Sales at Rs 47.17 crore, up 5.42% Y-o-Y
24.11.2025
Medicamen Bio Standalone September 2025 Net Sales at Rs 42.23 crore, down 1.44% Y-o-Y
09.09.2025
Medicamen Bio Standalone June 2025 Net Sales at Rs 38.45 crore, down 7.31% Y-o-Y
11.06.2025
Medicamen Bio Standalone March 2025 Net Sales at Rs 26.00 crore, down 42.24% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth